secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-070910
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica Q1 2025 net loss $5.9M; cash $24.6M; KOURAGE trial data due end of 2025
--------------------------------------------------------------------------------

- Net loss of $5.9M in Q1 2025 vs. net income of $0.1M in Q1 2024; R&D expenses rose to $4.2M.
- Cash, cash equivalents and short-term investments of $24.6M; runway expected into mid-2026.
- Phase 2 KOURAGE trial (AKI + respiratory failure) enrollment ongoing; data expected around end of 2025.
- Post-hoc analysis from CARDEA showed 62.7% relative mortality reduction for Auxora vs. placebo in AKI subset.
- End-of-Phase 2 meeting with FDA for AP/SIRS planned mid-2025; credit facility with Avenue Capital ($32.5M total).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000095017025070910/0000950170-25-070910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000095017025070910/ck0001534133-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer